Australia’s competition watchdog is no longer opposing Cochlear’s planned buy of rival implants provider after its competing bone conduction business was carved out of the deal. The Australian Competition and Consumer Commission (ACCC) flagged a challenge to the Cochlear’s planned $170 million acquisition of Oticon Medical from its Danish multinational parent company in 2022. Oticon…

The post ACCC waives through Cochlear’s revised rival buy appeared first on InnovationAus.com.

This post was originally published on InnovationAus.com.